Dianthus Therapeutics (DNTH) closed at $82.38 on October 30, 2026, down 0.4% from the previous close, on volume of 468,680 shares (30-day average 970,475).
Data as of October 30, 2026.
30-Oct-2026
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
Globe Newswire (Tue, 13-Oct 8:45 AM ET)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 1-Oct 5:00 PM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Globe Newswire (Mon, 10-Aug 4:07 PM ET)
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Globe Newswire (Mon, 3-Aug 6:00 PM ET)
Market Chameleon (Wed, 11-Mar 4:16 AM ET)
Dianthus Therapeutics Sparks Attention with Phase 3 CIDP Trial Update—Market Awaits Conference Call
Market Chameleon (Mon, 9-Mar 6:32 AM ET)
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.
As of October 30, 2026, DNTH stock price declined to $82.38 with 468,680 million shares trading.
DNTH has a beta of -0.08, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.
DNTH has a market cap of $4.61 billion. This is considered a Mid Cap stock.
Last quarter Dianthus Therapeutics reported $761,000 in Revenue and -$.90 earnings per share. This beat revenue expectation by $468,000 and exceeded earnings estimates by $.01.
In the last 3 years, DNTH traded as high as $117.88 and as low as $6.58.
The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, XBI, IWM, VXF, VB.
DNTH has outperformed the market in the last year with a price return of +144.2% while the SPY ETF gained +12.3%. However, in the short term, DNTH had mixed performance relative to the market. It has underperformed in the last 3 months, returning -26.9% vs +2.1% return in SPY. But in the last 2 weeks, DNTH shares have fared better than the market returning +14.3% compared to SPY -1.0%.
DNTH support price is $79.84 and resistance is $85.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.
